VitriVax
Biotechnology company developing thermostability and pulsatile dosing technology for vaccines and other sensitive biologics, enabling vaccine distribution without cold chain requirements.
Website
https://www.vitrivax.comLocation
Kansas City, Missouri, USA
Founded
2013
Investors
1
Categories
vaccines, drug-delivery, biotech, thermostability
Notes
VitriVax is a biotechnology company developing thermostability and pulsatile dosing technology for vaccines and other sensitive biologics. The company is headquartered in Kansas City, Missouri.
The company's technology addresses two major challenges in vaccine delivery:
- Thermostability: Most vaccines require cold chain storage and distribution, which is expensive and limits access in developing regions. VitriVax's technology can stabilize vaccines at room temperature.
- Pulsatile dosing: Many vaccines require multiple doses over time. VitriVax is developing single-injection formulations that release vaccine in pulses, mimicking a multi-dose regimen.
These innovations could significantly improve vaccine access and compliance globally.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Thermostability technology for vaccines
- Pulsatile dosing formulations
- Cold chain elimination potential
- Single-injection multi-dose delivery
- Kansas City, Missouri headquarters
- Founded in 2013
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |